Loading
A phase 1/2 trial of VMD-102 in hepatocellular carcinoma, uveal melanoma, renal cell carcinoma, non-small-cell lung cancer and colorectal cancer, run by VM Discovery, Inc., now recruiting.
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors is a phase 1/2 interventional study registered as NCT07636785 by VM Discovery, Inc., with 111 participants planned, started 2026-07-16 and due to reach its primary completion in 2031-05. Interventions recorded: VMD-102.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.